We are full of suspect cases. We don't have any space.
A rare strain of Ebola not seen in over a decade has re-emerged in eastern Democratic Republic of Congo, carrying with it the particular cruelty of arriving without a vaccine to meet it. Six hundred suspected cases and one hundred thirty-nine deaths have been recorded across Congo and Uganda, and the world's tools for fighting this specific virus — Bundibugyo — remain unfinished, months away from readiness. The United Kingdom has pledged twenty million pounds to shore up the human response, but in a region shaped by conflict, overwhelmed clinics, and a virus that disguises itself as ordinary illness, the gap between funding and containment is wide and consequential.
- A virus unseen for over a decade has returned with lethal speed, killing nearly one in four suspected cases and overwhelming healthcare facilities in one of the world's most fragile regions.
- No approved vaccine exists for the Bundibugyo strain, and the two experimental candidates in development are still six to nine months from readiness — leaving frontline workers and communities exposed with no targeted shield.
- Healthcare workers are among the dead, protective equipment has only just begun arriving, and staff report facilities so full of suspected cases that there is simply no space left.
- Early symptoms mimicking malaria and typhoid allowed the virus to spread undetected for weeks, meaning the true scale of the outbreak may already exceed what official numbers can capture.
- The UK's £20m pledge and a WHO international emergency declaration signal global alarm, but funding cannot compress the timeline for a vaccine, and eastern Congo's years of conflict complicate every step of the response.
- Communities in Bunia have already begun changing their behaviour — abandoning handshakes, bracing for worse — while international health authorities race to contain a crisis they acknowledge may deepen before it recedes.
On Wednesday, the World Health Organization confirmed six hundred suspected Ebola cases across the Democratic Republic of Congo and Uganda, with one hundred thirty-nine deaths. The strain responsible — Bundibugyo — has not circulated for more than a decade, and unlike the Zaire species that has driven Congo's seventeen previous outbreaks, it has no approved vaccine and no targeted treatment. Two experimental candidates are in development, but neither has entered clinical trials, and the most optimistic timeline places readiness at six to nine months away.
The outbreak traces back to a nurse in Bunia, capital of Ituri province, who died on April 24th. Her body was repatriated to Mongwalu, one of two gold-mining towns where cases have since clustered. Fifty-one cases have been confirmed in Congo, concentrated in Ituri and North Kivu, with two more in Uganda's capital, Kampala — both linked to travel from Congo, one already fatal. The WHO declared a public health emergency of international concern on Sunday.
On the ground, the situation is moving faster than the numbers suggest. Médecins Sans Frontières emergency manager Trish Newport relayed the message from health workers directly: facilities are full, there is no space, and staff remain inadequately protected even as personal protective equipment begins to arrive. Healthcare workers are among the dead — a warning sign about how rapidly the virus moves through medical settings.
Diagnosis has been a compounding problem. Ebola's early symptoms resemble malaria and typhoid, both endemic in eastern Congo, allowing the virus to spread before it was recognised. Residents in Bunia told the BBC they understand the danger and have already begun altering daily habits, abandoning handshakes and expecting conditions to worsen before they improve.
The United Kingdom announced a pledge of up to twenty million pounds to support frontline workers, infection control, and disease surveillance. WHO advisor Dr. Vasee Moorthy outlined the vaccine landscape: one candidate modelled on the existing Zaire vaccine could be ready in six to nine months; a second, built on the AstraZeneca COVID-19 platform, has no animal data yet, though doses for clinical trials might be available within two to three months. Neither offers near-term protection. In a region defined by conflict, limited infrastructure, and deep medical need, the next nine months will be the measure of whether this outbreak is contained or whether it becomes something far larger.
The World Health Organization delivered sobering news on Wednesday: six hundred suspected cases of Ebola have now been documented across the Democratic Republic of Congo and Uganda, with one hundred thirty-nine deaths recorded. But the most pressing concern may be what comes next—or rather, what does not come next. A vaccine against this particular strain of the virus, known as Bundibugyo, will not be ready for at least six to nine months, possibly longer. Two experimental candidates are in development, but neither has entered clinical trials.
Bundibugyo is not the Ebola strain the region knows. The Democratic Republic of Congo has weathered seventeen outbreaks of Ebola in its history, but those were predominantly caused by the Zaire species. Bundibugyo has not circulated for more than a decade. When it last appeared—in Uganda in 2007 and again in the Congo in 2012—it killed roughly one in three people who contracted it. The rarity of the virus means the world has fewer tools to contain it. There is no approved vaccine. There are no targeted drugs. The experimental vaccines under development operate on different platforms, and their effectiveness remains uncertain.
The outbreak began with a nurse in Bunia, the capital of Ituri province in eastern Congo, who developed symptoms and died on April 24th. Her body was repatriated to Mongwalu, one of two gold-mining towns where most cases have since clustered. Fifty-one cases have been confirmed in the Congo—concentrated in Ituri and North Kivu provinces—and two in Uganda's capital, Kampala. Both Ugandan cases involved people who had traveled from the Congo; one has already died. The WHO declared a public health emergency of international concern on Sunday, though it stopped short of calling it a pandemic.
The situation on the ground is deteriorating faster than the official numbers suggest. Healthcare facilities are overwhelmed. Trish Newport, an emergency programme manager with Médecins Sans Frontières, reported that health workers are telling her: "We are full of suspect cases. We don't have any space." Personal protective equipment has begun arriving, but staff remain inadequately protected. Healthcare workers themselves are among the dead—a particular concern that underscores how quickly the virus spreads in medical settings where people are most vulnerable.
The challenge of diagnosis compounds the crisis. Early symptoms of Ebola mimic malaria and typhoid, both common in eastern Congo. Many cases went unrecognized initially, allowing the virus to spread further before containment efforts could begin. Araali Bagamba, a lecturer living in Bunia, told the BBC that the population understands the danger. For three days, she said, she had not shaken anyone's hand—a break from a deeply ingrained social habit. People in the region believe the situation will worsen before it improves, precisely because the virus circulated undetected for so long.
The United Kingdom announced it will contribute up to twenty million pounds to contain the outbreak. The funding will support frontline health workers, strengthen infection control measures, and expand disease surveillance. Yet money alone cannot accelerate vaccine development. WHO advisor Dr. Vasee Moorthy explained that one candidate vaccine, modeled on the only approved Ebola vaccine currently available—which protects against Zaire—would likely take six to nine months to reach readiness. A second candidate, based on the same platform as the AstraZeneca COVID-19 vaccine, is being manufactured but has no animal data yet to support its effectiveness. Doses might be available for clinical trials in two to three months, but significant uncertainty remains.
Eastern Congo's vulnerability extends beyond the virus itself. The region has endured years of conflict, which complicates every aspect of outbreak response—from moving supplies to building trust with communities to maintaining healthcare infrastructure. The WHO chief, Dr. Tedros Adhanom Ghebreyesus, assessed the risk as high at the national and regional levels but low globally. He defended the organization's response against criticism from the United States, arguing that identifying the outbreak quickly in such a complex setting deserved recognition rather than reproach. Still, the mathematics are stark: a virus spreading in a region with limited medical resources, no approved vaccine, and no specific treatment, in a population where initial symptoms resemble common illnesses. The next nine months will determine whether containment holds or whether the numbers climb far beyond what anyone currently expects.
Notable Quotes
We know the scale of the epidemic in DRC is much larger. Healthcare workers are among those who have died, which is a particular concern.— WHO Chief Dr. Tedros Adhanom Ghebreyesus
For the last three days I haven't shaken anyone's hand. The habit has changed.— Araali Bagamba, lecturer in Bunia
The Hearth Conversation Another angle on the story
Why does it matter that this is Bundibugyo and not Zaire? Aren't they both Ebola?
They are, but Bundibugyo is the stranger in the room. The Congo knows Zaire. They have vaccines for Zaire, treatments developed over decades. Bundibugyo hasn't been seen in over ten years. When it last appeared, it killed one in three people. The world has almost no experience fighting it.
So the vaccine delay—is that unusual?
Not for a new outbreak, but the timing is brutal. Nine months is a long time when cases are doubling and healthcare workers are dying. In a region already fractured by conflict, where people can't tell Ebola from malaria, that delay means the virus spreads further before people even know what they're fighting.
The UK is putting in twenty million pounds. Is that enough?
It's a start. The money goes to protecting workers, improving surveillance, strengthening infection control. But money can't speed up vaccine trials or replace healthcare workers who are already dead. It's a holding action while the world waits for science to catch up.
You mentioned people stopped shaking hands. How much does that matter?
It matters because it shows people understand the danger. But understanding and changing behavior are different things in a place where handshakes are woven into daily life. Fear can change habits temporarily, but if the outbreak drags on, if people get tired or desperate, those habits return. That's when transmission accelerates again.
What happens if the vaccine isn't ready in nine months?
Then the outbreak likely continues spreading. Cases climb. More healthcare workers die. The region becomes more destabilized. And the world watches a virus it barely understands move through a population it can barely reach.